3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Ovarian Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lung Diseases
1
Glioblastoma
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Solid Tumors
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
zimberelimab
×
90 days
×
Clear all
No trials found.